To investigate autoantibodies related to excitation-contraction (E-C) coupling in patients with myasthenia gravis (MG), we developed a novel method to detect autoantibodies against dihydropyridine receptor (DHPR). Using this method, we detected DHPR antibody in 37% (11 out of 30) of MG patients with thymoma. Antibodies were not detected in normal nor disease controls. The titer of DHPR antibodies showed no significant correlation with autoantibodies to acetylcholine nor ryanodine receptors. The DHPR antibody is another marker for thymoma in MG, and it might have some role in clinical symptoms related to E-C coupling.
Myasthenia gravis (MG) is an autoimmune disease with impaired neuromuscular transmission mainly due to the effect of autoantibodies to acetylcholine receptor (AChR) (Conti-Fine et al., 2006) . Recently, dysregulation of sarcoplasmic reticulum (SR) Ca 2+ release has been associated with muscle fatigue (Bellinger et al., 2008 ). An electrophysiological study showed that fatigue in MG patients was caused not only by abnormal neuromuscular transmission but also by impairment of excitation-contraction (E-C) coupling (Pagala et al., 1993) . In the process of E-C coupling in skeletal muscle, ryanodine receptor (RyR) and dihydropyridine receptor (DHPR) function as Ca 2+ channels (Takeshima et al., 1994) . Autoantibody against RyR (RyR Ab) was previously detected from sera of MG patients with a large majority of them being associated with thymoma (Mygland et al., 1992; Takamori et al., 2004) . However, RyR is intracellular protein, and evidence that RyR Abs are pathogenic in vivo is still missing (Skeie et al., 2006) . Therefore, a new method to detect autoantibodies against other E-C coupling-related proteins facing to outside of muscle cells is necessary to explain the pathogenesis of the E-C coupling-impairment in MG. In this study, we developed a new method to detect specific autoantibodies against DHPR (DHPR Abs) and studied their frequency in MG patients.
Patients and methods

Patients
We examined serum samples from 57 patients with MG (male: 22; female: 35, with thymoma: 30; without thymoma: 27, ocular: 13; generalized: 44, AChR Ab-positive: 48; AChR Ab-negative: 9 [1; muscle-specific kinase (MuSK) Ab-positive], mean of onset age; 51.9 year-old), 14 patients with Lambert-Eaton myasthenic syndrome (LEMS), 35 disease controls (thymoma without MG: 7, other neurological disorders: 28) and 20 age-matched normal subjects. The clinical histories and laboratory data of patients were fully collected and reviewed by our physicians for the accuracy of diagnosis. Serum samples were drawn before the start of any immunosuppressive therapies and stocked at −20°C until measurement. Their titers of AChR Ab were measured by immunoprecipitation assay using 125 I-α-bungarotoxin labeled AChR from TE671 (Lindstrom et al., 1976) . Their titers of anti-P/Q-type voltage-gated calcium channel (VGCC) antibody (P/Q-VGCC Ab) were measured by immunoprecipitation assay using 125 I-ω-conotoxin MVIIC labeled P/Q-type VGCC from rat cerebellum (Motomura et al., 1997).
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